[摘要]目的：比较替格瑞洛和氯吡格雷在急性冠脉综合征（ACS）治疗中的

[Abstract] Objective: Comparison of the effect of clopidogrel and ticagrelor acute coronary syndrome (ACS) treatment. Methods: February 2017 - January 2019 hospital treated patients with ACS 146 as the research object, in accordance with the method divided into lottery clopidogrel and ticagrelor groups, each of the 73 cases, respectively, according to the grouping method administration of clopidogrel and ticagrelor treatment groups were compared before and after treatment of platelet agglutination, were compared with the clinical efficacy incidence of adverse reactions. Results: After the treatment, the two groups before treatment platelet aggregation rate was significantly decreased and was significantly lower than ticagrelor clopidogrel; ticagrelor treatment group was significantly higher than clopidogrel; Ruiluo group treatment of adverse events was significantly lower than that in the clopidogrel group. Group indexes within the above observation, the comparison between groups, the differences were statistically significant (P <0.05). Conclusion: Compared with clopidogrel, ticagrelor improve the status of platelet aggregation in patients with ACS is more effective, its clinical efficacy was significantly better than the former, and more secure.

Objective: To compare the effects of the application of tigreloid and clopidogrel in the treatment of acute coronary syndrome (ACS). Methods: Selected 146 ACS patients admitted to the hospital from February 2017 to January 2019 as the subject situ, divided them into chlorpidoghograd group and tigreloid group according to the drawing of lots, each of which was 73 cases, and were given two groups of patients in accordance with the group method, and compared the conditions of platelet clotting before and after treatment, compared the two groups of treatment before and after the platelet concentration, The incidence of clinical efficacy and adverse reactions was compared between the two groups. Results: After treatment, the concentration rate of both groups of platelets decreased significantly compared to pre-treatment, and the treatment efficiency of the greidagra group was significantly lower than that of the chlorpidogone group, and the incidence of adverse reactions in the Rilo group was significantly lower than that of the Clopidogre group. The differences in the comparison of the above-mentioned observation index group and between groups are statistically significant (both P 0.05). Conclusion: Compared with clopidogrel, the improvement effect of platelet aggregation in ACS patients was more significant, and its clinical efficacy was significantly better than that of the former, and it was more safe and reliable.

[Abstract] Objective: To compare the effect of tigril and clopidogrel in the treatment of acute coronary syndrome (ACS). Methods: 146 ACS patients admitted to our hospital from February 2017 to January 2019 were selected as the research objects. According to the method of drawing lots, they were divided into two groups: clopidogrel group and tegrilol group, 73 cases in each group. According to the grouping method, two groups were given clopidogrel and tegrilol respectively. The platelet aggregation, clinical effect and adverse reaction rate of the two groups were compared before and after treatment. Results: after the treatment, the platelet aggregation rate of the two groups was significantly lower than that before the treatment, and the effective rate of tegrilol group was significantly higher than that of clopidogrel group, and the incidence of adverse reactions in the group was significantly lower than that of clopidogrel group. There was significant difference between the two groups (P < 0.05). Conclusion: compared with clopidogrel, tegrarol is more effective in improving platelet aggregation in ACS patients, and its clinical effect is significantly better than the former, and it is more safe and reliable.<br>